38.62
-0.45 (-1.15%)
| Previous Close | 39.07 |
| Open | 39.20 |
| Volume | 2,446,371 |
| Avg. Volume (3M) | 766,249 |
| Market Cap | 1,734,126,976 |
| Price / Earnings (TTM) | 5.04 |
| Price / Book | 4.15 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Diluted EPS (TTM) | -2.20 |
| Total Debt/Equity (MRQ) | 0.05% |
| Current Ratio (MRQ) | 23.31 |
| Operating Cash Flow (TTM) | -66.65 M |
| Levered Free Cash Flow (TTM) | -42.10 M |
| Return on Assets (TTM) | -31.68% |
| Return on Equity (TTM) | -48.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | MBX Biosciences, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | -0.25 |
|
MBX Biosciences Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 3.12% |
| % Held by Institutions | 106.60% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Nea Management Company, Llc | 30 Sep 2025 | 3,614,486 |
| Nvp Associates, Llc | 30 Sep 2025 | 2,136,335 |
| Ecor1 Capital, Llc | 30 Sep 2025 | 2,123,604 |
| Kynam Capital Management, Lp | 30 Sep 2025 | 2,000,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 88.00 (Guggenheim, 127.86%) | Buy |
| Median | 60.00 (55.36%) | |
| Low | 18.00 (Goldman Sachs, -53.39%) | Sell |
| Average | 56.40 (46.04%) | |
| Total | 4 Buy, 1 Sell | |
| Avg. Price @ Call | 33.97 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 28 Jan 2026 | 66.00 (70.90%) | Buy | 35.83 |
| Guggenheim | 16 Jan 2026 | 88.00 (127.86%) | Buy | 40.53 |
| 10 Nov 2025 | 77.00 (99.38%) | Buy | 24.49 | |
| UBS | 07 Jan 2026 | 60.00 (55.36%) | Buy | 32.55 |
| Stifel | 19 Dec 2025 | 50.00 (29.47%) | Buy | 30.42 |
| Goldman Sachs | 04 Dec 2025 | 18.00 (-53.39%) | Sell | 30.54 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 22 Jan 2026 | Announcement | MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair |
| 11 Jan 2026 | Announcement | MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference |
| 15 Dec 2025 | Announcement | MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 |
| 18 Nov 2025 | Announcement | MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference |
| 06 Nov 2025 | Announcement | MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |